MLH1 and myasthenia gravis: In summary, the present study reveals that the promoter methylation levels of MLH1, MGMT, CDKN2A, and RASSF1A genes are not increased in thymomas with respect to the healthy tissues of patients with MG and do not correlate with histological or pathological features.